Answers are grounded in this paper and cite their sources.
CCND2 has context-dependent roles in cancer, but its prognostic relevance in the major histological subtypes of non-small cell lung cancer remains uncertain. We evaluated CCND2 separately in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) using The Cancer Genome Atlas (TCGA)data from OncoLnc and the Genomic Data Commons, together with three independent Gene Expression Omnibus (GEO) cohorts. Continuous-expression overall survival (OS) models were prespecified as the principal survival analyses. In matched tumor–normal pairs, CCND2 expression was lower in LUAD tumors (p < 0.001), with a nonsignificant difference in LUSC (p = 0.054). In TCGA-LUAD, higher CCND2 expression was associated with a lower mortality hazard after clinical adjustment (HR per SD = 0.839, 95% CI 0.722–0.975, p = 0.022; 0.841 without the pack-years-recorded indicator), with similar estimates in detailed-stage, EGFR-adjusted, and purity-adjusted models. The LUSC association was nonsignificant (HR = 0.888, 95% CI 0.776–1.017, p = 0.085), and a formal histology interaction test was nonsignificant (p = 0.235). Adding CCND2 to clinical models yielded only a small, uncertain gain in the C-index. External associations were heterogeneous and partly probe-dependent, and pooled estimates were nonsignificant in both histologies. Gene correlations were small, and pathway enrichments described bulk-tissue association patterns. CCND2 is an exploratory prognostic candidate in LUAD that requires further validation before clinical application.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: